These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35246476)

  • 1. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.
    Wang X; Zhou T; Chen X; Wang Y; Ding Y; Tu H; Gao S; Wang H; Tang X; Yang Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8
    Song F; Hu B; Liang XL; Cheng JW; Wang CG; Wang PX; Wang TL; Tang PJ; Sun HX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Clin Transl Med; 2024 Aug; 14(8):e1738. PubMed ID: 39095323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
    Xie P; Yu M; Zhang B; Yu Q; Zhao Y; Wu M; Jin L; Yan J; Zhou B; Liu S; Li X; Zhou C; Zhu X; Huang C; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Guo L; Li H
    J Hepatol; 2024 Jul; 81(1):93-107. PubMed ID: 38403027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
    Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
    Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J
    J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TOX promotes the exhaustion of antitumor CD8
    Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
    J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
    Lu JC; Zhang PF; Huang XY; Guo XJ; Gao C; Zeng HY; Zheng YM; Wang SW; Cai JB; Sun QM; Shi YH; Zhou J; Ke AW; Shi GM; Fan J
    J Hematol Oncol; 2021 Nov; 14(1):200. PubMed ID: 34838121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models.
    Lu X; Deng S; Xu J; Green BL; Zhang H; Cui G; Zhou Y; Zhang Y; Xu H; Zhang F; Mao R; Zhong S; Cramer T; Evert M; Calvisi DF; He Y; Liu C; Chen X
    J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37040183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.
    Rong D; Wang Y; Liu L; Cao H; Huang T; Liu H; Hao X; Sun G; Sun G; Zheng Z; Kang J; Xia Y; Chen Z; Tang W; Wang X
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
    Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
    Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
    Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
    Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
    Zhou C; Weng J; Liu C; Liu S; Hu Z; Xie X; Gao D; Zhou Q; Sun J; Xu R; Li H; Shen Y; Yi Y; Shi Y; Sheng X; Dong Q; Hung MC; Ren N
    Gastroenterology; 2023 Jun; 164(7):1261-1278. PubMed ID: 36863689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
    Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
    Front Immunol; 2022; 13():923031. PubMed ID: 35924241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
    Kim KJ; Lee HW; Seong J
    J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
    Xiong Z; Chan SL; Zhou J; Vong JSL; Kwong TT; Zeng X; Wu H; Cao J; Tu Y; Feng Y; Yang W; Wong PP; Si-Tou WW; Liu X; Wang J; Tang W; Liang Z; Lu J; Li KM; Low JT; Chan MW; Leung HHW; Chan AWH; To KF; Yip KY; Lo YMD; Sung JJ; Cheng AS
    Gut; 2023 Sep; 72(9):1758-1773. PubMed ID: 37019619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of ZNF207 in hepatocellular carcinoma and its significance].
    Zhou C; Li N
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Apr; 44(4):406-412. PubMed ID: 31113916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
    Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
    J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.